Indie Asset Partners, LLC Biogen Inc. Transaction History

Indie Asset Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $271,745 - $323,155	-1,449 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$193.77 - $244.14 $39,722 - $50,048	-205 Reduced 12.39%	1,449 $305,000
Q4 2021 Feb 11, 2022	BUY	$223.92 - $287.77 $11,196 - $14,388	50 Added 3.12%	1,654 $397,000
Q3 2021 Nov 09, 2021	SELL	$282.99 - $369.05 $7,074 - $9,226	-25 Reduced 1.53%	1,604 $454,000
Q2 2021 Aug 11, 2021	SELL	$259.0 - $414.71 $12,950 - $20,735	-50 Reduced 2.98%	1,629 $564,000

Q1 2021 May 13, 2021	BUY	$242.95 - $284.63 $128,763 - $150,853	530 Added 46.13%	1,679 $470,000
Q4 2020 Feb 09, 2021	BUY	$236.26 - $355.63 $271,462 - $408,618	1,149 New	1,149 $281,000

1,047

126M

1.37M

1.35M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $33B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Indie Asset Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Indie Asset Partners, LLC with notifications on news.